HER-2/neu Ile655Val Polymorphism and the Risk of Breast Cancer A Case-Control Study

被引:16
|
作者
Siddig, Awatif [2 ]
Mohamed, Abdelrahim Osman [3 ]
Kamal, Hammed [4 ]
Awad, Salma [5 ]
Hassan, Ahmed H. [5 ]
Zilahi, Erika [6 ]
Al-Haj, Mohammed [6 ]
Bernsen, Roos [7 ]
Adem, Abdu [1 ]
机构
[1] United Arab Emirates Univ, Dept Pharmacol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[2] Sudan Univ Sci & Technol, Fac Med Lab Technol, Khartoum, Sudan
[3] Univ El Imam El Mahdi, Fac Med & Hlth Sci, Dept Biochem, Kosti, Sudan
[4] Univ Khartoum, Fac Med, Dept Surg, Khartoum, Sudan
[5] United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[6] United Arab Emirates Univ, Dept Med Microbiol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[7] United Arab Emirates Univ, Dept Community Med, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
来源
RECENT ADVANCES IN CLINICAL ONCOLOGY | 2008年 / 1138卷
关键词
breast cancer; HER-2/neu; polymorphism; risk;
D O I
10.1196/annals.1414.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic alterations of the proto-oncogene human epidermal growth factor receptor (HER-2/neu) have been shown to induce malignant transformation and metastasis. Genotyping studies have addressed the association of codon 655 isoleucine to valine polymorphism located in the transmembrane coding region and the risk of breast cancer, but the results are inconsistent. In this study, we investigated the association of HER-2/neu Ile655Val polymorphism and the risk of breast cancer in a Sudanese population. In addition, the joint effects of HER-2/neu variants and our previously reported ESR1C325G polymorphism were tested for their association with breast cancer risk. Candidate single nucleotide polymorphism (SNP) in HER-2/neu Ile655Val [db SNP rs1136200] was genotyped in breast cancer patients and in healthy controls that were randomly selected from the same age group as the patients. Genotyping was performed using a high-throughput allelic discrimination method using real-time PCR, and data on clinical features and demographic details were collected. Associations between genotype and breast cancer were assessed by means of logistic regression. The prevalence of Val/Val genotype was similar in patients of breast cancer and control subjects. In comparison with the Ile/Ile genotype, the Ile/Val had a borderline significantly (P = 0.06) higher risk of breast cancer (OR = 2.95, 95% CI: 0.97-8.96). Regarding the genotypic and allelic frequencies stratified by age and menopausal status, there were no significant associations. A significantly higher risk of breast cancer was observed among homozygous carriers of ESR1325 CC genotype and heterozygous carriers of HER-2/neu655 Ile/Val genotype (P = 0.05; adjusted OR = 4.9, 95% Cl: 1.0-24). The association of HER-2/neu Ile655Val polymorphism and the risk of breast cancer was borderline significant with the heterozygous carrier being at higher risk. However, the frequency of different polymorphic variants varies with ethnicity. The results of this study suggest that a significant gene-gene interaction between ESR1325C (previously reported) and HER-2/neu Ile655Val variants may jointly contribute to a higher risk of breast cancer.
引用
收藏
页码:84 / 94
页数:11
相关论文
共 50 条
  • [31] A bias in genotyping the ERBB2 (HER2) Ile655Val variant
    Frank, B
    Hemminki, K
    Burwinkel, B
    CARCINOGENESIS, 2005, 26 (09) : 1649 - 1649
  • [32] Evaluation of Ile655Val HER2 Polymorphism Associated with Cardiac Toxicity Following the Administration of Trastuzumab in Women with Non-Metastatic Breast Cancer
    Diorio, C.
    Lemieux, J.
    Côté, M-A
    Provencher, L.
    Nadeau-Larochelle, C.
    Jacob, S.
    Demers, E.
    Tremblay-Lemay, R.
    Saint-Pierre, C.
    Beauchemin, M.
    Barabe, F.
    Laflamme, C.
    CANCER RESEARCH, 2011, 71
  • [33] Ile655Val of the HER2 gene and its possible predictive value in patients with hereditary breast and ovarian cancer syndrome
    Orozco-Quiyono, Martha
    Espinoza-Contreras, Fidel
    Sergio Rodriguez-Cuevas, A.
    Erazo Valle-Solis, Aura Argentina
    GACETA MEXICANA DE ONCOLOGIA, 2018, 17 (02): : 55 - 60
  • [34] Reply: a bias in genotyping of the ERBB2 (HER2) Ile655Val variant
    Benusiglio, PR
    Luccarini, C
    Ajai, O
    Ponder, BAJ
    Pharoah, PD
    CARCINOGENESIS, 2005, 26 (12) : 2213 - 2213
  • [35] The erbB2/HER2/neu receptor polymorphism IIe655Val and breast cancer
    Cox, DG
    Hankinson, SE
    Hunter, DJ
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (07): : 447 - 450
  • [36] HER-2基因Ile655Val多态性与结直肠癌易感性分析
    梁霞
    张勇晶
    刘冰
    倪勤
    金明娟
    马新源
    姚开颜
    李其龙
    陈坤
    中华医学遗传学杂志, 2009, (03) : 302 - 305
  • [37] Association of HER2 655 ile→Val polymorphism with pathological response to neoadjuvant chemotherapy and trastuzumab in breast cancer
    Astorga, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome
    Papadopoulou, E.
    Tripsianis, G.
    Anagnostopoulos, K.
    Tentes, I.
    Kakolyris, S.
    Galazios, G.
    Sivridis, E.
    Simopoulos, K.
    Kortsaris, A.
    NEOPLASMA, 2008, 55 (02) : 113 - 121
  • [39] Her-2/neu and breast cancer
    Kaptain, S
    Tan, LK
    Chen, BY
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2001, 10 (03) : 139 - 152
  • [40] HER-2 codon 655 single nucleotide polymorphism and HER-2 protein expression in ductal breast cancer
    Zubor, R.
    Kajo, K.
    Stanclova, A.
    Dokus, K.
    Fiolka, R.
    Visnovsky, J.
    Danko, J.
    BREAST, 2009, 18 : S27 - S28